Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Methylphenidate Generic Name & Formulations
Legal Class
CII
General Description
Methylphenidate HCl 5mg, 10mg+, 20mg+; tabs; dye-free; +scored.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
Manufacturer
Methylphenidate Indications
Indications
Attention deficit hyperactivity disorder.
Methylphenidate Dosage and Administration
Adult
10–60mg daily in 2–3 divided doses preferably 30–45 mins before meals. Chew tabs: take with 8oz of water or other fluid.
Children
<6yrs: not established. ≥6yrs: initially 5mg twice a day before breakfast and lunch. Increase gradually by 5–10mg per week if needed; max 60mg daily.
Methylphenidate Contraindications
Contraindications
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Methylphenidate Boxed Warnings
Boxed Warning
Drug abuse and dependence.
Methylphenidate Warnings/Precautions
Warnings/Precautions
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Pharmacokinetics
See Literature
Methylphenidate Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
Methylphenidate Clinical Trials
See Literature
Methylphenidate Note
Not Applicable
Methylphenidate Patient Counseling
See Literature
Methylphenidate Generic Name & Formulations
Legal Class
CII
General Description
Methylphenidate HCl 5mg, 10mg+, 20mg+; tabs; dye-free; +scored.
Pharmacological Class
CNS stimulant.
How Supplied
Tabs, ext-rel tabs, chew tabs—contact supplier; Oral soln—500mL
Manufacturer
Methylphenidate Indications
Indications
Narcolepsy.
Methylphenidate Dosage and Administration
Adult
10–60mg daily in 2–3 divided doses preferably 30–45 mins before meals. Chew tabs: take with 8oz of water or other fluid.
Children
<6yrs: not established. ≥6yrs: initially 5mg twice a day before breakfast and lunch. Increase gradually by 5–10mg per week if needed; max 60mg daily.
Methylphenidate Contraindications
Contraindications
During or within 14 days of MAOIs. Marked anxiety, tension, agitation. Glaucoma. Motor tics. Tourette's syndrome in patient or family.
Methylphenidate Boxed Warnings
Boxed Warning
Drug abuse and dependence.
Methylphenidate Warnings/Precautions
Warnings/Precautions
History of drug dependence or alcoholism; monitor for abnormal behavior. Increased risk of sudden death, stroke, and MI; assess for presence of cardiac disease before initiating. Avoid in known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, coronary artery disease, and other cardiac problems. Pre-existing psychotic disorder. Bipolar disorder; screen for risk before initiation. Consider discontinuing if new psychotic/manic symptoms occur. Monitor for new or worsening aggressive behavior or hostility. Seizure disorder. Peripheral vasculopathy, including Raynaud's Phenomenon; monitor for digital changes. Monitor growth (esp. children), BP, HR, CBCs, differential, platelet counts. Reduce dose or discontinue if paradoxical aggravation of symptoms occur. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Methylphenidate Pharmacokinetics
See Literature
Methylphenidate Interactions
Interactions
See Contraindications. Avoid alcohol. Hypertensive crisis with MAOIs. Caution with pressor agents. Antagonizes guanethidine. May potentiate coumarin anticoagulants, anticonvulsants (eg, phenobarbital, phenytoin, primidone), phenylbutazone, tricyclics, SSRIs. May antagonize antihypertensive drugs; monitor and adjust dose of antihypertensives as needed. Concomitant risperidone may increase risk of extrapyramidal symptoms; monitor.
Methylphenidate Adverse Reactions
Adverse Reactions
Insomnia, nervousness, CNS overstimulation, anorexia, weight loss, abdominal pain, nausea, dizziness, headache; priapism, hypertension, tachycardia, visual disturbances.
Methylphenidate Clinical Trials
See Literature
Methylphenidate Note
Not Applicable
Methylphenidate Patient Counseling
See Literature
